Serum Auto-Antibodies in Neurological Diseases
Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Jun 23, 2008
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The purposes of the study are to determine the frequency of auto-antibodies to 1) heat shock proteins and 2) to other molecules including cytoskeletal proteins such as rapsyn in diseases of the nervous system.
5cc of serum will be obtained from patients with multiple sclerosis and other autoimmune and inflammatory diseases of the nervous system including myasthenia gravis and transverse myelitis and from patients with other neurological diseases. Standard methodology to assure safe handling of serum will be used. Diluted serum will be tested for specific reactivity with heat shock proteins...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years or older
- • Diagnosis of multiple sclerosis, myasthenia gravis, or other autoimmune or inflammatory neurological disease
- Exclusion Criteria:
- • inability to give informed consent
About University Of California, Davis
The University of California, Davis (UC Davis) is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials and studies. With a strong focus on interdisciplinary collaboration, UC Davis leverages its extensive expertise in medical research, education, and patient care to drive breakthroughs in various fields, including medicine, public health, and agriculture. The university's clinical trial programs emphasize rigorous scientific methodology and ethical standards, aiming to translate research findings into impactful treatments and improved patient outcomes. Through its state-of-the-art facilities and a dedicated team of researchers and healthcare professionals, UC Davis is at the forefront of transforming healthcare practices and addressing critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Patients applied
Trial Officials
David Richman, MD
Principal Investigator
University of California, Davis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials